Intra-Cellular Therapies Inc reports results for the quarter ended in June - Earnings Summary

Intra-Cellular Therapies

09/08/2022 14:32

* Intra-Cellular Therapies Inc  ITCI.OQ  reported a
quarterly
adjusted loss of 92 cents​​ per share for the quarter ended in
June. The mean expectation of thirteen analysts for the quarter
was for a loss of 76 cents per share.
    * Revenue rose 177.2% to $55.58 million from a year ago;
analysts
expected $49.02 million. 
    * Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of 92 cents​.
    * The mean earnings estimate of analysts had risen by
about 6.3%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Intra-Cellular Therapies Inc shares had risen by 3.1% this
quarter and gained 12.4% so far this year.
    * The company reported a quarterly loss of $86.6 million.
    * Wall Street's median 12-month price target for
Intra-Cellular
Therapies Inc is $71.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 9
at 01:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.76          -0.92          Missed
 Mar. 31 2022      -0.92          -0.78          Beat
 Dec. 31 2021      -0.99          -1.05          Missed
 Sep. 30 2021      -0.92          -0.95          Missed